Karen Miotto, M.D.


Work Titles and Affiliation
UCLA Director, UCLA Addiction Psychiatry Service Associate Professor, Psychiatry and Biobehavioral Sciences
Education:
Degrees:
M.D., University of Colorado School of Medicine, 1989
Internship:
1989 - 1990 Reading Hospital & Medical Center
Residency:
1990 - 1993 UCLA Neuropsychiatric Hospital
Certifications:
Certifications:
1996 American Board of Psychiatry and Neurology
1995 American Board of Psychiatry and Neurology
1993 - 1994 UCLA Neuropsychiatric Hospital
Professional Societies:
Stewart and Lynda Resnick Neuropsychiatric Hospital at UCLA
Ronald Regan UCLA Medical Center

Contact Information:

Work Email Address:

kmiotto@mednet.ucla.edu


Website:

Work

Mailing Address:

UCLA Psychr & Biobehav Sci
BOX 951759, 760 Westwood Plaza, B8-233A Semel Institute
Los Angeles, CA 90095

Publications:

Ling Walter, Hillhouse Maureen, Jenkins Jessica, Miotto Karen, Torrington Matthew, Chapleo Christopher   Comparisons of Analgesic Potency and Side Effects of Buprenorphine and Buprenorphine With Ultra-low-dose Naloxone Journal of addiction medicine, 2012; 6(2): 118-23.
Miotto Karen, Kaufman Aaron, Kong Alexander, Jun Grace, Schwartz Jeffrey   Managing co-occurring substance use and pain disorders The Psychiatric clinics of North America, 2012; 35(2): 393-409.
Miotto Karen, Hillhouse Maureen, Donovick Roger, Cunningham-Rathner Jerry, Charuvastra Charlie, Torrington Matthew, Esagoff Asher E, Ling Walter   Comparison of buprenorphine treatment for opioid dependence in 3 settings Journal of addiction medicine, 2012; 6(1): 68-76.
Ray Lara A, Bujarski Spencer, Chin Pauline F, Miotto Karen   Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2012; 37(2): 445-55.
Ray Lara A, Chin Pauline F, Heydari Andia, Miotto Karen   A human laboratory study of the effects of quetiapine on subjective intoxication and alcohol craving Psychopharmacology, 2011; 217(3): 341-51.
Zorick Todd, Mandelkern Mark A, Lee Buyean, Wong Ma-Li, Miotto Karen, Shabazian Jon, London Edythe D   Elevated plasma prolactin in abstinent methamphetamine-dependent subjects The American journal of drug and alcohol abuse, 2011; 37(1): 62-7.
Zorick Todd, Nestor Liam, Miotto Karen, Sugar Catherine, Hellemann Gerhard, Scanlon Graham, Rawson Richard, London Edythe D   Withdrawal symptoms in abstinent methamphetamine-dependent subjects Addiction (Abingdon, England), 2010; 105(10): 1809-18.
Walwyn Wendy M, Miotto Karen A, Evans Christopher J   Opioid pharmaceuticals and addiction: the issues, and research directions seeking solutions Drug and alcohol dependence, 2010; 108(3): 156-65.
Ray Lara A, Chin Pauline F, Miotto Karen   Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics CNS & neurological disorders drug targets, 2010; 9(1): 13-22.
Zorick Todd, Sevak Rajkumar J, Miotto Karen, Shoptaw Steven, Swanson Aimee-Noelle, Clement Clayton, De La Garza Richard, Newton Thomas F, London Edythe D   Pilot Safety Evaluation of Varenicline for the Treatment of Methamphetamine Dependence Journal of experimental pharmacology, 2009; 2010(2): 13-18.
Al Ghananeem Abeer M, Herman Barbara H, Abbassi Maggie, Yu Elmer, Miotto Karen, O'Brien Charles P, Ling Walter, Montgomery Ann, Walsh Robert   Urine and plasma pharmacokinetics of lofexidine after oral delivery in opiate-dependent patients The American journal of drug and alcohol abuse, 2009; 35(5): 311-5.
Yu Elmer, Miotto Karen, Akerele Evaristo, Montgomery Ann, Elkashef Ahmed, Walsh Robert, Montoya Ivan, Fischman Marian W, Collins Joseph, McSherry Frances, Boardman Kathy, Davies David K, O'Brien Charles P, Ling Walter, Kleber Herbert, Herman Barbara H   A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal Drug and alcohol dependence, 2008; 97(1-2): 158-68.
Yu Elmer, Miotto Karen, Akerele Evaristo, O'Brien Charles P, Ling Walter, Kleber Herbert, Fischman Marian W, Elkashef Ahmed, Herman Barbara H, Al-Ghananeem Abeer M   Clinical pharmacokinetics of lofexidine, the alpha 2-adrenergic receptor agonist, in opiate addicts plasma using a highly sensitive liquid chromatography tandem mass spectrometric analysis The American journal of drug and alcohol abuse, 2008; 34(5): 611-6.
Rawson Richard A, McCann Michael J, Flammino Frank, Shoptaw Steven, Miotto Karen, Reiber Chris, Ling Walter   A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals Addiction (Abingdon, England), 2006; 101(2): 267-74.
Maglione Margaret, Miotto Karen, Iguchi Martin, Hilton Lara, Shekelle Paul   Psychiatric symptoms associated with ephedra use Expert opinion on drug safety, 2005; 4(5): 879-84.
Maglione Margaret, Miotto Karen, Iguchi Martin, Jungvig Lara, Morton Sally C, Shekelle Paul G   Psychiatric effects of ephedra use: an analysis of Food and Drug Administration reports of adverse events The American journal of psychiatry, 2005; 162(1): 189-91.
Compton Peggy, Miotto Karen, Elashoff David   Precipitated opioid withdrawal across acute physical dependence induction methods Pharmacology, biochemistry, and behavior, 2004; 77(2): 263-8.
London Edythe D, Simon Sara L, Berman Steven M, Mandelkern Mark A, Lichtman Aaron M, Bramen Jennifer, Shinn Ann K, Miotto Karen, Learn Jennifer, Dong Yun, Matochik John A, Kurian Varughese, Newton Thomas, Woods Roger, Rawson Richard, Ling Walter   Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers Archives of general psychiatry, 2004; 61(1): 73-84.
Miotto Karen, McCann Michael, Basch Janice, Rawson Richard, Ling Walter   Naltrexone and dysphoria: fact or myth? The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions, 2002; 11(2): 151-60.
Freese Thomas E, Miotto Karen, Reback Cathy J   The effects and consequences of selected club drugs Journal of substance abuse treatment, 2002; 23(2): 151-6.

MeSH Terms:

What is MeSH?

Medical Subject Headings

We have integrated Faculty Profiles with the U.S. National Library of Medicine's MeSH terms. For every publication added to a profile, we pull its MeSH terms and display it here. This enhancement allows you to search for research themes of our faculty members.

Click on any of the terms below to see additional researchers with similar keywords.

MeSH is:

  • an acronym for Medical Subject Headings.
  • the U.S. National Library of Medicine's controlled vocabulary (thesaurus).
  • a vocabulary that gives uniformity and consistency to the indexing and cataloging of biomedical literature.
  • a distinctive feature of MEDLINE.
  • arranged in a hierarchical manner called the MeSH Tree Structures.
  • updated annually.

MeSH Vocabulary includes four types of terms:

  • Headings
  • Subheadings
  • Supplementary Concept Records
  • Publication Characteristics (or Types)

Over 26,000 MeSH headings (also called "main headings" or "descriptors" represents concepts found in the biomedical literature

Subheadings - (also called qualifiers) are attached to MeSH headings to describe a specific aspect of a concept.

Supplementary Concept Records are over 200,000 terms in a separate thesaurus from the Medical Subject Headings. These are primarily substance terms, but also include some protocols and rare desease terms. These terms are updated weekly.

Publication Characteristics or (Publication Types) describe the type of publication being indexed; i.e., what the item is, not what the article is about.

Information from U.S. National Library of Medicine.

Administration, Oral Adult Adverse Drug Reaction Reporting Systems Alcoholic Intoxication Alcoholism Analgesics, Opioid Brain Chromatography, Liquid Chronic Pain Clonidine Depression Dietary Supplements Double-Blind Method Electroencephalography Ephedra Ethanol Humans Lorazepam Mental Disorders Methamphetamine Middle Aged Naltrexone Narcotic Antagonists Neuropsychological Tests Opioid-Related Disorders Pentobarbital Pilot Projects Plant Preparations Receptors, Opioid, mu Risk Factors Safety-Based Drug Withdrawals Sorption Detoxification Substance Withdrawal Syndrome Substance-Related Disorders Tandem Mass Spectrometry Young Adult

Does this profile need updating? Contact Us